Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway-Reference-Cited by-同舟云学术

Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway

Published:2019-01-08 Issue: Volume: Page:
ISSN:1019-6439
Container-title:International Journal of Oncology
language:
Short-container-title:Int J Oncol

Author:

Li Zhuo¹,Yu Dehai²,Li Haijun³,Lv You¹,Li Sijie⁴

Affiliation:

1. Endocrinology and Metabolism Department, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

2. Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

3. Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

4. Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crosstalk of methylation and tamoxifen in breast cancer (Review);Molecular Medicine Reports;2024-08-09

2. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer;Cell Death & Disease;2024-06-15

3. EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer;Biomedicine & Pharmacotherapy;2024-06

4. Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism;Non-coding RNA Research;2024-06

5. Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway;ChemistrySelect;2024-05-24